{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:38:10Z","timestamp":1784299090552,"version":"3.55.0"},"reference-count":95,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic sclerosis is an auto-immune disease characterized by skin involvement that often affects multiple organ systems. Pulmonary hypertension is a common finding that can significantly impact prognosis. Molecular pathophysiological mechanisms underlying pulmonary hypertension in systemic sclerosis can be extremely heterogeneous, leading to distinct clinical phenotypes. In addition, different causes of pulmonary hypertension may overlap within the same patient. Since pulmonary hypertension treatment is very different for each phenotype, it is fundamental to perform an adequate diagnostic work-up to properly and promptly identify the prevalent mechanism underlying pulmonary hypertension in order to start the right therapies. When pulmonary hypertension is caused by a primary vasculopathy of the small pulmonary arteries, treatment with pulmonary vasodilators, often in an initial double-combination regimen, is indicated, aimed at reducing the mortality risk profile. In this review, we describe the different clinical phenotypes of pulmonary hypertension in the scleroderma population and discuss the utility of clinical tools to identify the presence of pulmonary vascular disease. Furthermore, we focus on systemic sclerosis-associated pulmonary arterial hypertension, highlighting the advances in the knowledge of right ventricular dysfunction in this setting and the latest updates in terms of treatment with pulmonary vasodilator drugs.<\/jats:p>","DOI":"10.3390\/ijms21124430","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:11:02Z","timestamp":1592892662000},"page":"4430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3438-1537","authenticated-orcid":false,"given":"Umberto","family":"Attanasio","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-2865","authenticated-orcid":false,"given":"Alessandra","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-1898","authenticated-orcid":false,"given":"Stefania","family":"Loffredo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), 80131 Naples, Italy"},{"name":"World Allergy Organization (WAO), Center of Excellence, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Abete","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-4298","authenticated-orcid":false,"given":"Mario","family":"Petretta","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9849-4701","authenticated-orcid":false,"given":"Gianni","family":"Marone","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), 80131 Naples, Italy"},{"name":"World Allergy Organization (WAO), Center of Excellence, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Bonaduce","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"De Paulis","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), 80131 Naples, Italy"},{"name":"World Allergy Organization (WAO), Center of Excellence, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Wanda","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), 80131 Naples, Italy"},{"name":"World Allergy Organization (WAO), Center of Excellence, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-688X","authenticated-orcid":false,"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-2762","authenticated-orcid":false,"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences. Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/art.24525","article-title":"The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France","volume":"60","author":"Hachulla","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endo","volume":"37","author":"Humbert","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Launay, D., Sobanski, V., Hachulla, E., and Humbert, M. (2017). Pulmonary hypertension in systemic sclerosis: Different phenotypes. Eur. Respir. Rev., 26.","DOI":"10.1183\/16000617.0056-2017"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_7","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-010-8198-y","article-title":"Diagnosis and classification of systemic sclerosis","volume":"40","author":"Hachulla","year":"2011","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-019-0867-0","article-title":"Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis","volume":"21","author":"Hung","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Simonneau, G., Montani, D., Celermajer, D.S., Denton, C.P., Gatzoulis, M.A., Krowka, M., Williams, P.G., and Souza, R. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J., 53.","DOI":"10.1183\/13993003.01913-2018"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00019501-200502000-00003","article-title":"The right ventricle in pulmonary hypertension","volume":"16","author":"Chin","year":"2005","journal-title":"Coron. Artery Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/2045893217700438","article-title":"Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction","volume":"7","author":"Bourji","year":"2017","journal-title":"Pulm. Circ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00296-015-3382-2","article-title":"Cardiac involvement in systemic sclerosis: Differences between clinical subsets and influence on survival","volume":"37","author":"Pizzi","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_14","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: A simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"A53","DOI":"10.1186\/ar3987","article-title":"Risk of pulmonary embolism and deep vein thrombosis in systemic lupus erythematosus: A population-based cohort study","volume":"14","author":"Lacaille","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Martinez, C., Wallenhorst, C., Teal, S., Cohen, A.T., and Peacock, A.J. (2018). Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. Pulm. Circ., 8.","DOI":"10.1177\/2045894018791358"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"924A","DOI":"10.1378\/chest.2268147","article-title":"PVOD Is Highly Prevalent in Scleroderma Patients Undergoing Lung Transplant","volume":"148","author":"Gupta","year":"2015","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1378\/chest.12-2396","article-title":"Systemic sclerosis-associated pulmonary arterial hypertension","volume":"144","author":"Chaisson","year":"2013","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s10067-013-2307-2","article-title":"Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: A systematic review of the literature","volume":"32","author":"Yang","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jaafar, S., Visovatti, S., Young, A., Huang, S., Cronin, P., Vummidi, D., McLaughlin, V., and Khanna, D. (2019). Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.00586-2019"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.00078411","article-title":"ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a","volume":"39","author":"Hurdman","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: A systematic review and meta-analysis","volume":"65","author":"Dauchet","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Frost, A., Badesch, D., Gibbs, J.S.R., Gopalan, D., Khanna, D., Manes, A., Oudiz, R., Satoh, T., Torres, F., and Torbicki, A. (2019). Diagnosis of pulmonary hypertension. Eur. Respir. J., 53.","DOI":"10.1183\/13993003.01904-2018"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s11547-013-0934-1","article-title":"Ipertensione polmonare e sclerodermia: Il ruolo della TC ad alta risoluzione","volume":"118","author":"Zompatori","year":"2013","journal-title":"Radiol. Medica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"Maitre","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Galie","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1183\/09031936.00091212","article-title":"High prevalence of occult left heart disease in scleroderma-pulmonary hypertension","volume":"42","author":"Fox","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lammi, M.R., Saketkoo, L.A., Gordon, J.K., and Steen, V.D. (2018). Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: Insights from the PHAROS cohort. Pulm. Circ., 8.","DOI":"10.1177\/2045893218757404"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2045894018785247","DOI":"10.1177\/2045894018785247","article-title":"Phenotyping pulmonary hypertension in systemic sclerosis: A moving target","volume":"8","author":"Mercurio","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-Terminal Pro-Brain Natriuretic Peptide as a Diagnostic Marker of Early Pulmonary Artery Hypertension in Patients with Systemic Sclerosis and Effects of Calcium-Channel Blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2005-916152","article-title":"The role of exercise testing in the management of pulmonary arterial hypertension","volume":"26","author":"Oudiz","year":"2005","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_36","first-page":"423","article-title":"Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension","volume":"35","author":"Martins","year":"2009","journal-title":"J. Bras. Pneumol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.112.000008","article-title":"Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension","volume":"6","author":"Tedford","year":"2013","journal-title":"Circ. Hear. Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1701436","DOI":"10.1183\/13993003.01436-2017","article-title":"Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension","volume":"50","author":"Mukherjee","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC\/ERS-Based Risk Assessment Strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/680356","article-title":"Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: Two distinct phenotypes","volume":"5","author":"Kelemen","year":"2015","journal-title":"Pulm. Circ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1161\/CIRCULATIONAHA.116.022082","article-title":"Right ventricular functional reserve in pulmonary arterial hypertension","volume":"133","author":"Hsu","year":"2016","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1161\/CIRCULATIONAHA.117.033147","article-title":"Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension","volume":"137","author":"Hsu","year":"2018","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.201704-0789LE","article-title":"Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma-associated pulmonary arterial hypertension","volume":"197","author":"Mercurio","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/ar2534","article-title":"Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies","volume":"10","author":"Nannini","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"143637","DOI":"10.1155\/2012\/143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: A meta-analysis","volume":"2012","author":"Tzouvelekis","year":"2012","journal-title":"Pulm. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"King, C.S., and Shlobin, O.A. (2020). The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. Chest.","DOI":"10.1016\/j.chest.2020.04.046"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/phar.2314","article-title":"Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review","volume":"39","author":"Kido","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vachi\u00e9ry, J.L., Delcroix, M., Al-Hiti, H., Efficace, M., Hutyra, M., Lack, G., Papadakis, K., and Rubin, L.J. (2018). Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur. Respir. J., 51.","DOI":"10.1183\/13993003.01886-2017"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/IBPC.S232038","article-title":"Management of pulmonary arterial hypertension in patients with systemic sclerosis","volume":"13","author":"Almaaitah","year":"2020","journal-title":"Integr. Blood Press. Control."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Olschewski","year":"2008","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","article-title":"Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)\u2014A subgroup analysis of the ARIES-E clinical trial","volume":"117","author":"Fischer","year":"2016","journal-title":"Respir. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Denton","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.2174\/0929867325666180201095743","article-title":"New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension","volume":"26","author":"Mercurio","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","article-title":"Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"192","author":"Rhee","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"A999","DOI":"10.1016\/j.chest.2017.08.1036","article-title":"OPUS Registry: Treatment Patterns and Safety of Macitentan in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (PAH-SSc)","volume":"152","author":"Chin","year":"2017","journal-title":"Chest"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"A874","DOI":"10.1016\/j.chest.2019.08.827","article-title":"Macitentan in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease: Real-World Evidence From the Combined Opus\/Orpheus Data Sets","volume":"156","author":"McLaughlin","year":"2019","journal-title":"Chest"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"Patent Plus: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Scalise","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMc051946","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_67","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Brundage","year":"2009","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S2213-2600(14)70013-X","article-title":"Tadalafil in patients with chronic obstructive pulmonary disease: A randomised, double-blind, parallel-group, placebo-controlled trial","volume":"2","author":"Goudie","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Fransen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (patent-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gaine, S., Chin, K., Coghlan, G., Channick, R., Di Scala, L., Gali\u00e8, N., Ghofrani, H.A., Lang, I.M., McLaughlin, V., and Preiss, R. (2017). Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur. Respir. J., 50.","DOI":"10.1183\/13993003.02493-2016"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X","article-title":"Systemic sclerosis-associated pulmonary hypertension: Short- and long- term effects of epoprostenol (prostacyclin)","volume":"42","author":"Klings","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ejim.2011.02.005","article-title":"Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease","volume":"22","author":"Caravita","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gali\u00e8, N., Channick, R.N., Frantz, R.P., Gr\u00fcnig, E., Jing, Z.C., Moiseeva, O., Preston, I.R., Pulido, T., Safdar, Z., and Tamura, Y. (2019). Risk stratification and medical therapy of pulmonary arterial hypertension. Eur. Respir. J., 53.","DOI":"10.1183\/13993003.01889-2018"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Boucly, A., Weatherald, J., Savale, L., Ja\u00efs, X., Cottin, V., Prevot, G., Picard, F., De Groote, P., Jevnikar, M., and Bergot, E. (2017). Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur. Respir. J., 50.","DOI":"10.1183\/13993003.00889-2017"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Hoeper, M.M., Kramer, T., Pan, Z., Eichstaedt, C.A., Spiesshoefer, J., Benjamin, N., Olsson, K.M., Meyer, K., Vizza, C.D., and Vonk-Noordegraaf, A. (2017). Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur. Respir. J., 50.","DOI":"10.1183\/13993003.00740-2017"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1800497","DOI":"10.1183\/13993003.00497-2018","article-title":"Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: Application of the ESC\/ERS risk prediction model","volume":"52","author":"Mercurio","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/eurheartj\/ehq152","article-title":"Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses","volume":"31","author":"Gali","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","article-title":"Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the seraphin trial","volume":"18","author":"Jansa","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): Subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_91","unstructured":"(2020, March 15). NCT02682511 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension, Available online: Https:\/\/clinicaltrials.gov\/show\/nct02682511."},{"key":"ref_92","unstructured":"(2016, December 02). NCT02981082 Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension, Available online: https:\/\/clinicaltrials.gov\/show\/nct02981082."},{"key":"ref_93","unstructured":"(2017, March 06). EUCTR2016-004793-17-DE Bardoxolone Methyl Evaluation in Patients with Pulmonary Hypertension (PH). Available online: http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-004793-17-DE."},{"key":"ref_94","unstructured":"(2010, March 15). NCT01086540 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH), Available online: https:\/\/clinicaltrials.gov\/show\/nct01086540."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zamanian, R., Badesch, D., Chung, L., Domsic, R., Medsger, T., Pinckney, A., Keyes-Elstein, L., D\u2019Aveta, C., Spychala, M., and White, J. (2019). Late Breaking Abstract\u2014Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.congress-2019.RCT1884"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:10Z","timestamp":1760175670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21124430"],"URL":"https:\/\/doi.org\/10.3390\/ijms21124430","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]}}}